Evidence map›Paper›PMID 41276286›Full record

ArticleZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2026

[Functional characterization of double-negative T cells isolated from leukoreduction filter residues].

Zhiqiang Xiang, Yue Wu, Kaiyu Huang, Fuqiang Wu, Ju Lin, Lieyong Sang, Liming Yang

Abstract readEnglish Abstract
In one paragraph

Article in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhiqiang XiangGraduate School, Zhejiang Chinese Medical University, Hangzhou 310053, China. xiangzq@126.com.
Yue WuWyze Biotech CO., Ltd., Shaoxing 312065, Zhejiang Province, China.
Kaiyu HuangWyze Biotech CO., Ltd., Shaoxing 312065, Zhejiang Province, China.
Fuqiang WuWyze Biotech CO., Ltd., Shaoxing 312065, Zhejiang Province, China.
Ju LinShaoxing Municipal Blood Center, Shaoxing 312071, Zhejiang Province, China.
Lieyong SangShaoxing Municipal Blood Center, Shaoxing 312071, Zhejiang Province, China. 363729994@qq.com.
Liming YangWyze Biotech CO., Ltd., Shaoxing 312065, Zhejiang Province, China. lyang@wyzebiotech.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo characterize the biological properties of double-negative T (DNT) cells isolated from leukoreduction filter residues.

methodsLeukoreduction filters containing residues from 400 mL whole blood units (

resultsThe leukocyte recovery rate achieved through reverse flushing of the leukocyte reduction filter was (41.9±14.7)%. Compared to whole blood, the DNT cells starting material obtained from filter residues showed no significant difference in total T-cells content (

conclusionsDNT cells derived from leukoreduction filter residues exhibited highly comparable characteristics to those from whole blood in terms of expansion, purity, differentiation, and biological potency. Furthermore, their biological activity post-cryopreservation and revival remained largely similar to non-cryopreserved cells. These findings suggest that leukoreduction filter residues represent a promising alternative source of starting material for manufacturing off-the-shelf, allogeneic DNT cell therapeutics.

Indexed as

Leukocyte Reduction ProceduresT-LymphocytesCell SeparationHumansCell activityCell cryopreservingCell cultureDouble negative T cellsLeukocyte reduction filterLeukoreduction filter residues

Identifiers

PMID41276286
PMCPMC12980120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.